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Abstract We investigated whether discodermolide, a novel
antimitotic agent, a¡ects the binding to microtubules of tau
protein repeat motifs. Like taxol, the new drug reduces the
proportion of tau that pellets with microtubules. Despite their
di¡ering structures, discodermolide, taxol and tau repeats all
bind to a site on L-tubulin that lies within the microtubule lumen
and is crucial in controlling microtubule assembly. Low concen-
trations of tau still bind strongly to the outer surfaces of pre-
formed microtubules when the acidic C-terminal regions of at
least six tubulin dimers are available for interaction with each
tau molecule; otherwise binding is very weak.
" 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Discodermolide, a novel antimitotic drug isolated from a
deep-sea sponge, binds to microtubules more potently than
taxol, stabilises them against disassembly better than taxol
and is e¡ective even at 4‡C [1,2]. Now that it can be fully
synthesised [3], it has entered clinical trials as a chemothera-
peutic agent for use against taxol-resistant cancers. Even
though it bears no obvious structural resemblance to taxoid
molecules (Fig. 1), it can displace taxol [4]. Taxol was ¢rst
shown to bind to a speci¢c site on L-tubulin in studies of zinc-
induced sheets of tubulin proto¢laments [5], which have since
allowed the atomic structure of the complex to be resolved [6^
8]. When proto¢laments are assembled into microtubules, this
binding pocket lies inside the lumen [9^11].
Microtubules are very labile polymers when assembled from
pure tubulin but their stability can be controlled by a variety
of molecules. A widespread family of structural microtubule-
associated proteins (MAPs), including tau, MAP2 and MAP4,
which maintain the stability of tubulin polymers, is character-
ised by a conserved sequence repeat motif [12,13]. By labelling
one of the conserved repeat motifs in the microtubule-stabil-
ising protein tau with nano-gold and co-assembling tubulin
and labelled tau in the absence of drugs, we recently showed
by three-dimensional (3D) electron cryomicroscopy that this
region of the microtubule-binding domain locates to the inside
surface of L-tubulin, in the region of the taxol-binding pocket
[14]. If assembly occurs in the presence of taxol, there is a
reduction in the proportion of tau that binds to and pellets
with the microtubules. We now ¢nd that discodermolide is
more consistent than taxol in reducing the proportion of tau
in the pellets. The more e¡ective properties of the new drug
have also allowed us to further clarify the interactions be-
tween microtubules and tau. We conclude from our binding
curves that low concentrations of tau still bind strongly to the
outside surface, even when discodermolide blocks the repeat
domains from binding to the inner sites, mainly because of
association between each tau molecule and the acidic C-ter-
mini of six tubulin dimers. If the C-termini are removed by
subtilisin digestion, tau binds only very weakly to prestabi-
lised microtubules.
2. Materials and methods
2.1. Puri¢cation of tubulin, S-tubulin and tau
Tubulin was puri¢ed from pig brain extracts by standard methods
involving cycles of warming/cooling and centrifugation, followed by
chromatography on phosphocellulose resin. The bu¡er used for puri-
¢cation and assembly was BRB80 (80 mM PIPES, pH 6.9, 2 mM
MgCl2, 1 mM ethyleneglycol-bis-(L-aminoethylether)-N,N,NP,NP-tet-
raacetic acid (EGTA)).
The C-termini of both tubulin monomers were digested with the
enzyme subtilisin to produce S-tubulin using the method of Chau et
al. [15] ; the full extent of digestion was con¢rmed by Western blotting
with antibodies to K- and L-tubulin [14].
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Fig. 1. The chemical structures of discodermolide (a) and taxol (b)
show no obvious similarity.
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Tau, containing three repeat domains (with the sequence of 37 kDa
human tau), was expressed in Escherichia coli and puri¢ed by Method
1 in [14], in order to ensure full tubulin assembly-promoting activity.
2.2. Preparation of discodermolide
Stereocontrolled synthesis of (+)-discodermolide was carried out as
described [3]. For use in these experiments it was dissolved in dimethyl
sulphoxide (DMSO) to a concentration of 1 mM and subsequently
diluted to 20 WM in BRB80.
2.3. Pelleting assays
Tubulin was thawed from liquid nitrogen and spun at 77 300Ug for
20 min. Its concentration was determined spectroscopically. Since tau
has a very low absorbance, its concentration was estimated by sodium
dodecyl sulphate^polyacrylamide gel electrophoresis (SDS^PAGE),
against a bovine serum albumin (BSA) standard and tau protein of
known concentration. Varying concentrations of tau were incubated
with 10 WM tubulin, 0.1 M trimethylamine-N-oxide (TMAO), 1 mM
guanosine triphosphate (GTP), and 5% DMSO and incubated for 20
min at 37‡C. After centrifugation at 96 600Ug for 40 min the super-
natants were carefully removed and the pellets were resuspended in 40
Wl of BRB80. Pellets and supernatants were run on SDS^PAGE, and
the gels were stained with Page Blue83. For pelleting in the presence
of discodermolide, the drug was added to tubulin prior to polymeri-
sation and tau was added either at the same time or after microtubule
assembly.
3. Results and discussion
3.1. Tau in microtubule pellets, with and without
discodermolide
We carried out microtubule pelleting assays with a constant
amount of tubulin and varying amounts of a tau isotype con- taining three conserved repeats in its microtubule-binding do-
main, as described previously [14]. Before centrifugation, the
proteins were incubated together at 37‡C, in the presence or
absence of 20 WM discodermolide. The pellets and superna-
tants were run on 10% SDS gels (Fig. 2a). At low ratios of
tau:tubulin dimer, tau bound tightly to the pelleted micro-
tubules. Without drugs, tau appeared in the supernatant
when the ratio was about 1:3 [14] but in the presence of
discodermolide, unbound tau was detected at a 1:4 ratio
and larger amounts were seen in each supernatant at higher
concentrations (Fig. 2b). The results were similar whether the
drug was added to soluble tubulin at the same time as tau, or
was used to stabilise preformed microtubules before the addi-
tion of tau. The reduction in bound tau is more distinct at all
concentrations than we found in the presence of taxol [14],
consistent with discodermolide’s stronger stabilisation of mi-
crotubules. TMAO, an agent that stabilises the folding of
numerous proteins [16] including tau [17], was included in
our bu¡ers, though it is not essential if tau is puri¢ed in a
way that ensures full activity [14].
Observations that taxol reduces the amounts of tau that
bind to microtubules and 3D electron microscopy of micro-
tubules co-assembled with tau molecules that had been la-
belled with nano-gold on one of the repeat motifs originally
suggested that binding of the repeat motifs overlaps the drug-
binding sites on L-tubulin [14]. Because discodermolide binds
more tightly than taxol does to tubulin, the binding curves
shown here support this model more clearly. Discodermolide
and taxol compete for binding to microtubules [1,2] and elec-
tron crystallographic studies also indicate they have overlap-
ping binding sites (K.H. Downing, personal communication).
We conclude that the binding sites of both drugs overlap with
that of tau repeat motifs. The corresponding site on the
K-tubulin subunit is ¢lled by an extended loop with the pri-
Fig. 2. a: SDS gel of proteins in pellets (P) and supernatants (S)
when 3 WM of three-repeat tau was incubated at 37‡C with 10 WM
tubulin in the absence (control) or presence of 20 WM discodermo-
lide and then centrifuged [14]. Tubulin was either native or digested
with subtilisin (S-tub). b: Binding curves for varying amounts of
tau added to 10 WM microtubules under the conditions shown in a.
c: Scatchard plots better display the transition from strong binding
(dissociation constant V1037 M, from slope of line), at low ratios
of tau to tubulin, to weak binding (V1036 M) at higher ratios.
Without any drug, one repeat motif of tau binds strongly to each
tubulin dimer (3.3 WM tau to 10 WM tubulin). With discodermolide
present, one complete tau molecule binds fairly strongly to V6 tu-
bulin dimers (1.7 WM tau to 10 WM tubulin).
Fig. 3. a: Distribution of positively charged (blue circles) and nega-
tively charged (red diamonds) protein residues within the various
domains of htau40, the longest form of human tau (diagram modi-
¢ed from [26]). Note that the concentration of negative charges is
lower in the proline-rich domain. The htau37 used for the experi-
ments in Fig. 2 is identical except it has only three repeat motifs in-
stead of four. b: Tentative scheme for the preferred interactions of
di¡erent regions of tau with a microtubule. Tubulin heterodimers
are shown green. The N-terminal region (red line) of tau projects
from the outer surface. The proline-rich region (blue) of tau inter-
acts with each tubulin monomer via the negatively charged tubulin
C-termini (red ovals, shown for only one proto¢lament). The repeat
region (purple) of tau interacts with the inner surface of the micro-
tubule [14]. Current data do not provide information about the pre-
ferred location of the C-terminal region of tau.
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mary sequence TVVPGGDL. The most similar sequence with-
in the tau repeat domain is THVPGGGN. However, there is
no obvious relationship between the structures of these amino
acids and either of the drug molecules.
3.2. How does tau interact with the microtubule outer surface?
In our model for the incorporation of tau into microtubules
during co-assembly, the C-terminal one-third of a tau mole-
cule binds to the inner surfaces of tubulin subunits in such a
way that, ideally, each tau repeat motif interacts with one
tubulin dimer. The N-terminal projection domain extends
from the outer surface, while some part of the central region
must thread its way through the microtubule wall via the gaps
between tubulin proto¢laments, in order to connect the N-
terminal and C-terminal portions. In the presence of discoder-
molide or taxol, low concentrations of tau still bind fairly well
(Fig. 2c), even if the tau is added to preassembled closed
tubes, when it seems likely that it can only bind to the outside.
Binding to the outer surface primarily involves regions of tau
other than the repeats, since a three-repeat domain by itself
(K19) bound poorly to taxol-stabilised microtubules, while a
construct that lacked any repeats (K23) bound almost as well
as complete three-repeat tau [18].
When we incubated prestabilised microtubules overnight
with the enzyme subtilisin to completely remove the acidic
carboxyl terminals of all K- and L-tubulin monomers, tau
bound only weakly (Figs. 2b, c), in agreement with earlier
¢ndings [15,19^22]. The distribution of tau’s charged amino
acids (Fig. 3a) suggests that the proline-rich region is most
likely to partner the acidic regions on the outer surface of a
microtubule (Fig. 3b). The position at which the line in the
Scatchard plot (Fig. 2c) abruptly changes its slope when sites
on the inside surface are blocked by drugs indicates that bind-
ing remains strong only if each tau molecule can interact on
the outside surface with six or more tubulin dimers (i.e. at
least 48 nm along a proto¢lament). This contrasts with the
need for interactions with only three tubulin dimers for tau to
be very strongly bound in the absence of drugs. The proline-
rich region alone is not long enough to contact six separate
tubulin dimers, either along a proto¢lament or even across
adjacent proto¢laments. But when bound drugs restrict the
entire tau molecule to interacting with the outer surface of
the microtubule, the repeat motifs and the C-terminus of
tau can also stick to tubulin’s highly charged C-termini and
thus contribute to the overall binding strength [23]. Indeed,
when taxol-stabilised microtubules decorated with tau or
MAP2c under such conditions were studied by 3D electron
cryomicroscopy [22], density that could be attributed to the
MAPs or to a gold label attached to the repeat domain was
detected only on the outermost ridges of the proto¢laments, in
contact with the C-termini of the tubulin subunits.
3.3. A versatile binding site on L-tubulin?
Discodermolide reduces the proportion of total tau that
binds to microtubules even more e¡ectively than taxol, sug-
gesting that these two dissimilar drugs and the repeat motifs
of MAPs all have a common binding site on the inside surface
of L-tubulin. Being highly conserved across all eukaryotic spe-
cies, it cannot have adapted to bind a range of di¡erent li-
gands that are found only in speci¢c organisms (like marine
sponges or yew trees) and thereby induce cell death. More
probably, it is so versatile because it has evolved to accom-
modate a variety of proteins that control microtubule stability
under di¡erent circumstances. Since this site on L-tubulin is
ideally situated to control the conformation of the tubulin
proto¢lament and its lateral interactions with neighbouring
proto¢laments [24], it may be used to bind a range of alter-
native protein sequence motifs in other MAPs. Interestingly,
taxol has been shown to reversibly abolish the binding of
EB1, a protein found concentrated on the plus ends of micro-
tubules [25]. But this protein family has no conserved se-
quence motif that is obviously similar to tau or MAP2 repeats
and it remains to be shown whether any other types of MAPs
bind to microtubules in an equivalent way to the repeat motifs
of tau.
Acknowledgements: We thank Drs M. Goedert and J. Fan for help
and advice. I.P. thanks the EPSRC and the EC (HPRN-CT-2000-
00018) for support.
References
[1] Hung, D.T., Chen, J. and Schreiber, S.L. (1996) Chem. Biol. 3,
287^293.
[2] ter Haar, E., Kowalski, R.J., Hamel, E., Lin, C.M., Longley,
R.E., Gunasekera, S.P., Rosenkranz, H.S. and Day, B.W.
(1996) Biochemistry 35, 243^250.
[3] Paterson, I., Florence, G.J., Gerlach, K., Scott, J.P. and Sereinig,
N. (2001) J. Am. Chem. Soc. 123, 9535^9544.
[4] Balachandran, R., ter Haar, E., Welsh, M.J., Grant, S.G. and
Day, B.W. (1998) Anticancer Drugs 9, 67^76.
[5] Nogales, E., Wolf, S.G., Khan, I.A., Luduena, R.F. and Dow-
ning, K.H. (1995) Nature 375, 424^427.
[6] Nogales, E., Wolf, S.G. and Downing, K.H. (1998) Nature 391,
199^203.
[7] Snyder, J.P., Nettles, J.H., Cornett, B., Downing, K.H. and
Nogales, E. (2001) Proc. Natl. Acad. Sci. USA 98, 5312^5316.
[8] Lo«we, J., Li, H., Downing, K.H. and Nogales, E. (2001) J. Mol.
Biol. 313, 1045^1057.
[9] Nogales, E., Whittaker, M., Milligan, R.A. and Downing, K.H.
(1999) Cell 96, 79^88.
[10] Meurer-Grob, P., Kasparian, J. and Wade, R.H. (2001) Bio-
chemistry 40, 8000^8008.
[11] Li, H., DeRosier, D., Nicholson, W., Nogales, E. and Downing,
K. (2002) Structure 10, 1317^1328.
[12] Goedert, M., Baur, C.P., Ahringer, J., Jakes, R., Hasegawa, M.,
Spillantini, M.G., Smith, M.J. and Hill, F. (1996) J. Cell Sci. 109,
2661^2672.
[13] Heidary, G. and Fortini, M.E. (2001) Mech. Dev. 108, 171^178.
[14] Kar, S., Fan, J., Smith, M.J., Goedert, M. and Amos, L.A.
(2003) EMBO J. 22, 70^78.
[15] Chau, M.F., Radeke, M.J., deIne¤s, C., Barasoain, I., Kohlstaedt,
L.A. and Feinstein, S.C. (1998) Biochemistry 37, 17692^17703.
[16] Hill, C.M., Bates, I.R., White, G.F., Hallett, F.R. and Harauza,
G. (2002) J. Struct. Biol. 139, 13^26.
[17] Tseng, H.-C. and Graves, D.J. (1998) Biochem. Biophys. Res.
Commun. 250, 726^730.
[18] Gustke, N., Trinczek, B., Biernat, J., Mandelkow, E.M. and
Mandelkow, E. (1994) Biochemistry 33, 9511^9522.
[19] Serrano, L., Avila, J. and Maccioni, R.B. (1984) Biochemistry 23,
4675^4681.
[20] Hagiwara, H., Yorifuji, H., Satoyoshitake, R. and Hirokawa, N.
(1994) J. Biol. Chem. 269, 3581^3589.
[21] Saoudi, Y., Paintrand, I., Multigner, L. and Job, D. (1995) J. Cell
Sci. 108, 357^367.
[22] Al-Bassam, J., Ozer, R.S., Safer, D., Halpain, S. and Milligan,
R.A. (2002) J. Cell Biol. 157, 1187^1196.
[23] Goode, B.L., Denis, P.E., Panda, D., Radeke, M.J., Miller, H.P.,
Wilson, L. and Feinstein, S.C. (1997) Mol. Biol. Cell 8, 353^365.
[24] Amos, L.A. (2000) Curr. Opin. Struct. Biol. 10, 236^241.
[25] Morrison, E.E., Wardleworth, B.N., Askham, J.M., Markham,
A.F. and Meredith, D.M. (1998) Oncogene 17, 3471^3477.
[26] Goedert, M., Jakes, R., Spillantini, M.G. and Crowther, R.A.
(1994) in: Microtubules (Hyams, J. and Lloyd, C., Eds.), Wiley,
New York.
FEBS 27067 12-3-03 Cyaan Magenta Geel Zwart
S. Kar et al./FEBS Letters 539 (2003) 34^3636
